6 recruiting. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 6 |
| Phase 2 | 2 | Recruiting 2 |
Follow Social Behavior: new trials by email Literature Review of Social Behavior trials Research Report on Social Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients Methylprednisolone, Prednisone - Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas | Phase 3 | Recruiting | University of Sydney | 540 | 2026-03-13 | 2026-08-31 |
| Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection | Phase 2 / Phase 3 | Recruiting | Columbia University | 150 | 2025-09-12 | 2026-10-02 |
| Food-Body-Mind Intervention (16 Weeks) Food-Body-Mind - Mental Health Wellness, Emotional Problem | Phase 2 / Phase 3 | Recruiting | Michigan State University | 800 | 2024-08-14 | 2026-10-05 |
| Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Rabbit Anti thymocyte globulin (rATG), Basiliximab - Renal Transplant Rejection, Induction Therapy | Phase 3 | Recruiting | University Hospital, Tours | 244 | 2023-11-07 | 2026-06-18 |
| A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification - BK Viremia, Kidney Transplant Infection | Phase 3 | Recruiting | The University of Queensland | 280 | 2023-08-18 | 2026-06-08 |
Rejection, Psychology (5) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Diseases (1) · Liver Diseases (1) · Pediatric Obesity (1) · Social Skills (1) · Virus Diseases (1)
Behavior (6) · Body Weight (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Infections (1) · Male Urogenital Diseases (1) · Nervous System Diseases (1) · Nervous System Malformations (1) · Neurodegenerative Diseases (1)
Antilymphocyte Serum (1) · Basiliximab (1) · Cyclosporine (1) · Everolimus (1) · Immunoglobulins, Intravenous (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Prednisone (1) · Steroids (1) · Tacrolimus (1) · Valganciclovir (1) · letermovir (1)
Columbia University (1) · Hannover Medical School (1) · Michigan State University (1) · The University of Queensland (1) · University Hospital, Tours (1) · University of Sydney (1)
Australia (2) · United States (2) · Canada (1) · France (1) · Germany (1) · New Zealand (1)
Germaine Wong, PhD, FRACP (1) · Germaine Wong, Professor (1) · Julie Ho, FRCPC (1) · Richard Taubert, Professor (1)
PMID 30903722, PMID 39352862, PMID 39382091, PMID 41265832
2025 (1)